RecruitingPhase 1NCT07205289
Serum Collection Study for Assay Development
A Phase 1B Open-label Study to Collect Serum Following Vaccination With Killed Whole-cell Pneumococcal Vaccine (Gamma-PN) in Adults for Use in Assay Validation
Sponsor
GPN Vaccines
Enrollment
12 participants
Start Date
Oct 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
Eligibility
Min Age: 18 YearsMax Age: 69 Years
Inclusion Criteria1
- good general health
Exclusion Criteria1
- no previous pneumococcal vaccine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALGamma-PN
Killed whole-cell pneumococcal vaccine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07205289
Related Trials
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
NCT071354531 location
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
NCT067313742 locations
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
NCT060440771 location
A randomised controlled trial of pneumococcal conjugate vaccines Synflorix and Prevenar13 in sequence or alone in high-risk Indigenous infants (PREV-IX): immunogenicity, carriage and otitis media outcomes
ACTRN126100005440771 location